Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 816 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Hable con su médico sobre las opciones de cirugía de mama February 13, 2024 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 Sparing the Hippocampus During PCI Better Preserves Cognitive Function in Patients... August 19, 2021 Load more HOT NEWS Noninferiority of OS with 3 Months Compared to 6 Months of... Experimental Drug Prevents Doxorubicin from Harming the Heart Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs... EMA Recommends Extension of Indications for Darolutamide
